Asia Pacific Wearable Injectors Market is expected to reach US$ 2939.97 Mn by 2027

On-body injectors segment by type is estimated to lead the market growth during the forecast period

According to The Insight Partners market research study of “Asia-Pacific wearable injectors Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type, Application and End User,” the Asia-Pacific wearable injectors market is projected to reach US$ 2939.97 million by 2027 from US$ 1160.40 million in 2019. The market is estimated to grow at CAGR of 12.4% from 2020 to 2027. The report highlights trends prevailing in the Asia-Pacific wearable injectors market and the factors driving market along with those that act as hindrances.

Based on type, the wearable injectors market is segmented into on-body injectors and off-body injectors. The on-body injectors segment held the largest share of the market in 2019. However, the off-body injectors segment is estimated to register the highest CAGR of 13.0% in the market during the forecast period.

An on-body injector is a wearable injection device. These devices are becoming popular with cancer patients in the wearable injectors market. Once the device is implemented to the stomach or arm, it slowly delivers the medication over some time. This allows patients to be treated at home without exposure to other infections during treatment. The convenience is making the wearable injectors one of the most in-demand in the forecast period.

Wearable injectors are subcutaneous drug delivery systems that adhere to the body and administer larger volumes (more than 2 mL) of the drug over an extended period. With the use of wearable injectors, needle stick injuries can be avoided that are caused during parenteral drug administration using injections. Therefore, wearable injectors make them desirable for the treatment of chronic diseases where long-term treatment is necessary. Chronic diseases, such as diabetes, cardiovascular disorders, neurological disorders, autoimmune disorders, and various types of cancer, are the leading causes of death and disability worldwide. Cardiovascular diseases (CVDs) are a significant cause of mortality globally owing to the hectic lifestyle.

Many biologics are commercially available for the treatment, but the conventional drug delivery methods are unable to provide accurate dosage. This augments the use of wearable injector drug delivery systems providing targeted drug delivery and prolonged drug residence to the affected areas of the cardiovascular system. Hence, the adoption of wearable injectors is likely to increase, which, in turn, propels the market growth.

Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and can increase the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. According to the International Diabetes Federation (IDF), in 2019, 88 million adults (20-79) are living with diabetes in the South-East Asia Region and is expected to increase to 153 million by 2045. In diabetes patients, the exogenous insulin is usually administered through a subcutaneous route of administration for diabetes management. The wearable injector is an ideal drug delivery method for painless and accurate dosage of insulin.

Asia-Pacific wearable injectors Market is expected to grow owing to factors such as increasing chronic diseases prevalence, technological advancements and design development, and conventional drug delivery system. However, the market is likely to have negative impact due to lack of adoption in emerging countries

BD, CeQur SA, Debiotech S.A., E3D Elcam Drug Delivery Devices, Gerresheimer AG, Tandem Diabetes Care Inc, West Pharmaceutical Services, Inc, Ypsomed AG, Medtronic, Amgen, Inc. Are among the leading companies operating in the Asia-Pacific wearable injectors Market.

Asia-Pacific wearable injectors  Market, By Country, 2019 (% share)

---

Asia Pacific Wearable Injectors Market to Grow at a CAGR of 12.4% to reach US$ 2939.97 Million from 2020 to 2027

Download Free Sample

---

Asia Pacific Wearable Injectors Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type (On-Body Injectors, Off-Body Injectors); Application (Diabetes, Oncology, Cardiovascular Disease, Autoimmune Disease, Other Applications); End User (Hospitals and Clinics, Homecare Setting, Other End User), and, Country

The report segments Asia-Pacific wearable injectors market as follows:

By Type

• On-body Injectors
• Off-body Injectors

By Application

• Diabetes
• Oncology
• Cardiovascular Disease
• Autoimmune Disease
• Other Applications

By End User

• Hospitals and Clinics
• Homecare Setting
• Other End User

By Country

• China
• Japan
• India
• South Korea
• Australia
• RoAPAC